CN110613735B - Application of NK cell exosome hsa-miR-9609 in antibiosis - Google Patents
Application of NK cell exosome hsa-miR-9609 in antibiosis Download PDFInfo
- Publication number
- CN110613735B CN110613735B CN201911001160.7A CN201911001160A CN110613735B CN 110613735 B CN110613735 B CN 110613735B CN 201911001160 A CN201911001160 A CN 201911001160A CN 110613735 B CN110613735 B CN 110613735B
- Authority
- CN
- China
- Prior art keywords
- hsa
- mir
- exosome
- tumor
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 73
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 21
- 230000003115 biocidal effect Effects 0.000 title abstract description 11
- 108091070501 miRNA Proteins 0.000 claims abstract description 41
- 239000002679 microRNA Substances 0.000 claims abstract description 35
- 238000002360 preparation method Methods 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 abstract description 17
- 206010028980 Neoplasm Diseases 0.000 abstract description 15
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 15
- 230000000259 anti-tumor effect Effects 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 14
- 210000004881 tumor cell Anatomy 0.000 abstract description 7
- 230000005764 inhibitory process Effects 0.000 abstract description 5
- 239000003242 anti bacterial agent Substances 0.000 abstract description 4
- 230000000845 anti-microbial effect Effects 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 3
- 229940088710 antibiotic agent Drugs 0.000 abstract description 2
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- 238000001228 spectrum Methods 0.000 abstract description 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 238000006386 neutralization reaction Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 32
- 241000194032 Enterococcus faecalis Species 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 21
- 241000194017 Streptococcus Species 0.000 description 16
- 241000588923 Citrobacter Species 0.000 description 12
- 230000012010 growth Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 8
- 241000191967 Staphylococcus aureus Species 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 5
- 102000001398 Granzyme Human genes 0.000 description 5
- 108060005986 Granzyme Proteins 0.000 description 5
- 239000012510 hollow fiber Substances 0.000 description 5
- 108091066902 Homo sapiens miR-330 stem-loop Proteins 0.000 description 4
- 241000191963 Staphylococcus epidermidis Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 201000008968 osteosarcoma Diseases 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 241000588626 Acinetobacter baumannii Species 0.000 description 3
- 108091068941 Homo sapiens miR-106a stem-loop Proteins 0.000 description 3
- 108091069094 Homo sapiens miR-134 stem-loop Proteins 0.000 description 3
- 108091069002 Homo sapiens miR-145 stem-loop Proteins 0.000 description 3
- 108091065453 Homo sapiens miR-296 stem-loop Proteins 0.000 description 3
- 108091070365 Homo sapiens miR-30a stem-loop Proteins 0.000 description 3
- 108091055449 Homo sapiens miR-4463 stem-loop Proteins 0.000 description 3
- 241000588747 Klebsiella pneumoniae Species 0.000 description 3
- 208000003445 Mouth Neoplasms Diseases 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 241000588770 Proteus mirabilis Species 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 201000007455 central nervous system cancer Diseases 0.000 description 3
- 208000025997 central nervous system neoplasm Diseases 0.000 description 3
- 229940032049 enterococcus faecalis Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 3
- 201000005962 mycosis fungoides Diseases 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229930192851 perforin Natural products 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000588697 Enterobacter cloacae Species 0.000 description 2
- 208000021309 Germ cell tumor Diseases 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000033014 Plasma cell tumor Diseases 0.000 description 2
- 208000007452 Plasmacytoma Diseases 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 2
- 241000191984 Staphylococcus haemolyticus Species 0.000 description 2
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000000244 kidney pelvis Anatomy 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 208000025440 neoplasm of neck Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 208000010626 plasma cell neoplasm Diseases 0.000 description 2
- 229940055019 propionibacterium acne Drugs 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- -1 salt ions Chemical class 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 101100165655 Arabidopsis thaliana BRO1 gene Proteins 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 206010070545 Bacterial translocation Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100025222 CD63 antigen Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 208000017259 Extragonadal germ cell tumor Diseases 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- 241000192016 Finegoldia magna Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 1
- 101100082597 Homo sapiens PDCD6IP gene Proteins 0.000 description 1
- 108091067618 Homo sapiens miR-181a-2 stem-loop Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010062038 Lip neoplasm Diseases 0.000 description 1
- 208000000265 Lobular Carcinoma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000004059 Male Breast Neoplasms Diseases 0.000 description 1
- 206010025557 Malignant fibrous histiocytoma of bone Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000010505 Nose Neoplasms Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000000160 Olfactory Esthesioneuroblastoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 1
- 206010033963 Parathyroid tumour Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 102000004503 Perforin Human genes 0.000 description 1
- 108010056995 Perforin Proteins 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010057846 Primitive neuroectodermal tumour Diseases 0.000 description 1
- 102100033344 Programmed cell death 6-interacting protein Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 208000008938 Rhabdoid tumor Diseases 0.000 description 1
- 206010073334 Rhabdoid tumour Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000192087 Staphylococcus hominis Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241001291896 Streptococcus constellatus Species 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 241001312524 Streptococcus viridans Species 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 208000000728 Thymus Neoplasms Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000007375 bacterial translocation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 201000007180 bile duct carcinoma Diseases 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000003714 breast lobular carcinoma Diseases 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
- 201000007273 ductal carcinoma in situ Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- 229940092559 enterobacter aerogenes Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 208000018279 extrahepatic bile duct neoplasm Diseases 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 201000000284 histiocytoma Diseases 0.000 description 1
- 201000008298 histiocytosis Diseases 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
- 201000002529 islet cell tumor Diseases 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 201000011061 large intestine cancer Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 201000003175 male breast cancer Diseases 0.000 description 1
- 208000010907 male breast carcinoma Diseases 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 208000037830 nasal cancer Diseases 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 201000008859 olfactory neuroblastoma Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 208000007312 paraganglioma Diseases 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 208000020943 pineal parenchymal cell neoplasm Diseases 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 208000037968 sinus cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 208000014680 small intestine neoplasm Diseases 0.000 description 1
- 229940037649 staphylococcus haemolyticus Drugs 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 201000009377 thymus cancer Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 208000029387 trophoblastic neoplasm Diseases 0.000 description 1
- 208000017997 tumor of parathyroid gland Diseases 0.000 description 1
- 208000025444 tumor of salivary gland Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 208000018417 undifferentiated high grade pleomorphic sarcoma of bone Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses an exosome secreted by NK cells (aNK) activated by transmembrane IL-21, and application of various miRNAs contained in the exosome in antibiosis, neutralization and antitumor, and provides a new idea for treating bacterial infection and resisting tumors. The method comprises the following steps: (1) unlike antibiotic therapy, exosome antibiotics have lower side effects; (2) the antibacterial treatment effect can be enhanced by the combined use; (3) exosome can be stored at low temperature, miRNA can be artificially synthesized, cost is low, and large-scale production can be realized; (4) exosome and multiple miRNAs have inhibition effects on multiple bacteria, and have wide antimicrobial spectrum; (5) the miRNA acts on a signal path shared by multiple tumor cells, can inhibit multiple tumors, and has wide anti-tumor application.
Description
The application is a divisional application with the application number of 2017113093652, the application date of 2017, 12 and 11, and the invention name of application of NK cell exosomes and related miRNA in antibiosis and antitumor.
Technical Field
The present invention relates to exosomes (exosomes) secreted by transmembrane IL-21 activated NK cells (aNK), and the use of related mirnas in antibacterial, neutralizing and antitumor applications.
Background
Exosomes are nanoscale membrane vesicles which are secreted by cells and carry cytoplasmic components, are secreted by various cells of an organism, and are widely distributed in body fluids such as saliva, plasma, milk and the like. Exosomes contain a variety of bioactive substances such as proteins, mRNA, and miRNA. Exosomes deliver miRNA and proteins to other cells in a membrane fusion as a bridge for cell-to-cell communication.
NK cells are the major effector cells of the innate immune system and have been used in the treatment of tumors by releasing perforin and granzyme that kill infected or cancerous cells. The exosome secreted by the NK cell contains partial active substances of the NK cell and also has the capacity of resisting tumors.
The biggest bottleneck of applying NK cell exosomes to clinical treatment is that because NK cells cannot be well amplified in vitro, a sufficient amount of exosomes cannot be obtained. To solve this problem, we use transmembrane IL-21 expressed by artificial antigen-presenting cells (aAPCs) to stimulate the proliferation of NK cells, which are amplified in sufficient numbers to meet the needs of clinical treatment. After 14-18 days of activation and amplification, a large number of exosomes are released into a culture solution by aNK cells, and the aNK cell exosomes have typical NK cell characteristic proteins and have killing capacity on various tumor cells.
The widespread use of antibiotics has led to an alarming rate increase in the frequency of microbial resistance and its associated serious infectious diseases over the past decades. Among the gram-positive bacteria, the most important drug-resistant pathogens are methicillin-resistant staphylococcus aureus, beta-lactam-resistant pneumococcus and multidrug-resistant pneumococcus, as well as vancomycin-resistant enterococci. Beta-lactamase drug resistance in gram-negative bacteria such as Klebsiella pneumoniae, Escherichia coli and Proteus mirabilis is an important cause of drug resistance of gram-negative bacteria. There is therefore an urgent need for novel antibacterial agents, especially those with a novel mechanism of action, for clinical treatment.
The invention discovers that the exosomes of the activated aNK cells are rich in not only cytoplasmic components of the NK cells, but also a large amount of miRNA. The miRNA can obviously inhibit the growth of bacteria in experiments and has an excellent antibacterial function, and meanwhile, the miRNA can inhibit the growth of tumor cells in experiments and has an anti-tumor function.
Disclosure of Invention
The invention aims to provide an exosome secreted by aNK cells and application of miRNA contained in the exosome in antibiosis and antitumor.
The purpose of the invention is realized by the following technical scheme: an application of transmembrane IL-21 activated secretion of NK cells in antibacterial.
Further, the exosome comprises one or more miRNA selected from the sequences shown in SEQ ID NO. 1-SEQ ID NO. 2144.
Further, the exosome is used for antibacterial alone, or the exosome is used for antibacterial together with aNK cells.
Any one miRNA shown in SEQ ID NO. 1-SEQ ID NO. 1411.
The application of any one miRNA shown in SEQ ID NO. 1-SEQ ID NO.2144 in antibiosis.
Further, it is used for preparing antibacterial agent.
Further, bacteria targeted include, but are not limited to: escherichia coli (Escherichia coli), Staphylococcus aureus (Staphylococcus aureus), Klebsiella pneumoniae (Klebsiella pneumoniae), Pseudomonas aeruginosa (Pseudomonas aeruginosa), Enterococcus faecium (Enterococcus faecalis), Staphylococcus epidermidis (Staphylococcus epidermidis), Enterococcus faecalis (Enterococcus faecalis), group B Streptococcus (Streptococcus Gr. B), Acinetobacter baumannii (Acinetobacter baumannii), Proteus mirabilis (Proteus mirabilis), Staphylococcus hemolyticus (Staphylococcus haemolyticus), Staphylococcus hominis (Staphylococcus aureus), Enterobacter cloacae (Enterobacter cloacae), Mycobacterium tuberculosis (Mycobacterium tuberculosis), Mycobacterium albicans (Streptococcus faecalis), Staphylococcus albus (Staphylococcus albus), Streptococcus albicans (Streptococcus faecalis), Streptococcus faecalis (Streptococcus), Streptococcus faecalis (Streptococcus faecalis), Streptococcus faecalis (Bacillus), Streptococcus faecalis (Streptococcus), Streptococcus faecalis (Corynebacterium), Streptococcus faecalis (Bacillus), Streptococcus faecalis), Streptococcus faecalis (Bacillus), Streptococcus faecalis (Bacillus), Streptococcus faecalis (Bacillus), Streptococcus faecalis (Bacillus), Streptococcus (Bacillus spp (Bacillus), Streptococcus faecalis (Bacillus), Streptococcus (Bacillus), Streptococcus faecalis (Bacillus), Streptococcus (Bacillus), Streptococcus faecalis (Bacillus), Streptococcus faecalis (Bacillus), Streptococcus faecalis (Bacillus spp (Bacillus), Streptococcus faecalis (Bacillus), Streptococcus (Bacillus), Streptococcus faecalis (Bacillus spp), Streptococcus faecalis (Bacillus spp), Streptococcus strain (Bacillus spp), Streptococcus strain (Bacillus spp), Streptococcus strain (Bacillus spp), Streptococcus strain (Bacillus spp), Streptococcus strain (Bacillus spp), Bacillus strain (Bacillus spp), Streptococcus strain (Bacillus spp), Bacillus strain (Bacillus spp), Bacillus strain (Bacillus, Propionibacterium acnes (Propionibacterium acnes), Finegolderia macrocephala (Finegoldia magna), Staphylococcus reoccus (Staphylococcus aureus), Enterobacter aerogenes (Enterobacter aeogens), Streptococcus stellatus (Streptococcus constellatus), and Streptococcus viridis (Streptococcus viridans).
Application of miRNA shown in SEQ ID NO. 1-SEQ ID NO.1411 in preparing anti-tumor preparation.
Further, types for tumors include, but are not limited to: acute lymphocytic leukemia, acute myeloid leukemia, adrenocortical carcinoma, AIDS-related cancers, anal cancer, astrocytoma, atypical teratocarcinoma/rhabdoid tumor, central nervous system tumor, basal cell carcinoma-skin carcinoma (non-melanoma), bile duct carcinoma, bladder cancer, bone tumor, osteosarcoma, malignant fibrous histiocytoma, brain stem glioma, brain tumor, breast cancer, bronchial tumor, central nervous system tumor, cervical cancer, chordoma, Chronic Lymphocytic Leukemia (CLL), Chronic Myelogenous Leukemia (CML), chronic myeloproliferative disease, colon cancer, large intestine cancer, craniopharyngioma, cutaneous T-cell lymphoma-mycosis fungoides, ductal carcinoma in situ, embryonic tumor, central nervous system tumor, endometrial cancer, ependymoma, esophageal cancer, olfactory neuroblastoma, ewing's sarcoma family tumor, extracranial germ cell tumor, extragonadal germ cell tumor, extrahepatic bile duct tumor, eye cancer, osteochondral histiocytoma, osteosarcoma, gallbladder cancer, stomach cancer, gastrointestinal carcinoid, gastrointestinal stromal tumor-adult soft tissue sarcoma, germ cell tumor, gestational trophoblastic tumor, glioma, hairy cell leukemia, head and neck cancer, heart tumor, liver cancer, histiocytosis, Langerhans cell, Hodgkin's lymphoma, hypopharynx cancer, intraocular melanoma, islet cell tumor (endocrine pancreas), Karposi's sarcoma, kidney cancer, Langerhans cell histiocytosis, laryngeal cancer, leukemia, lip and oral cancer, liver cancer, lobular carcinoma, lung cancer, lymphoma, macroglobulinemia, male breast cancer, malignant fibrous histiocytoma of bone, osteosarcoma, medulloblastoma, and myeloepithelial tumors, melanoma, malignant mesothelioma, metastatic squamous carcinoma neck tumor, oral cancer, multiple endocrine tumor syndrome, multiple myeloma/plasma cell tumor, mycosis fungoides, myelodysplastic syndrome, myelodysplastic/myeloproliferative tumor, chronic myelogenous leukemia, myeloid leukemia, multiple myeloma, myeloproliferative disease, nasal sinus tumor, nasopharyngeal cancer, neuroblastoma, non-hodgkin's lymphoma, non-small cell lung cancer, oral cancer, liporopharyngeal cancer, osteosarcoma, malignant fibrous histiocytoma bone, ovarian cancer pancreatic cancer, papilloma, paraganglioma, sinus and nasal cancer, parathyroid tumor, penile cancer, pharyngeal cancer, pheochromocytoma, pineal parenchymal tumor, pituitary tumor, plasma cell tumor/multiple myeloma, pleuropulmonary blastoma, primary Central Nervous System (CNS) lymphoma, prostate cancer, rectal cancer, renal cell (kidney) cancer, renal pelvis and ureter, transitional cell carcinoma, respiratory tract cancer, retinoblastoma, rhabdomyosarcoma, salivary gland tumor, skin cancer, small cell lung cancer, small bowel tumor, soft tissue sarcoma, squamous carcinoma neck tumor, primitive neuroectodermal tumor, T-cell lymphoma, testicular cancer, throat cancer, thymoma and thymus cancer, thyroid cancer, trophoblastic tumors, ureter and renal pelvis transitional cell cancer, urinary tract cancer, uterine sarcoma, vaginal cancer, vulval cancer, waldenstrom's macroglobulinemia and wilms' tumor.
The invention has the beneficial effects that: the invention provides a means different from antibiotic antibiosis and antitumor, exosome secreted by aNK cells and related miRNA are used for antibiosis and antitumor, and the side effect is greatly reduced while the treatment effect is enhanced; a large number of experiments prove that the exosome and the related miRNA have inhibition effects on bacteria and tumors, and the inhibition effects are derived from the inhibition of the exosome or the related miRNA on a signal path shared by the bacteria or tumor cells. In addition, the exosome can be stored at low temperature, miRNA can be artificially synthesized, the cost is low, and large-scale production can be realized; moreover, the combined use of such exosomes and aNK cells will further enhance the antibacterial effect.
Drawings
FIG. 1 particle size distribution plot of aNK exosomes extracted via a hollow fiber tangential filtration system;
FIG. 2 is a diagram of protein expression of Werstern blot assay aNK exosomes;
FIG. 3 is a transmission electron microscope observation aNK exosome morphology and size chart;
FIG. 4 is a graph of miRNA wien analysis in aNK;
FIG. 5 aNK exosomes inhibit multiple bacterial growth patterns;
FIG. 6A NK exosome growth profile inhibiting Citrobacter;
figure 7 aNK exosomes in combination with NK cells effect on bacterial translocation in mouse intestinal tract;
FIG. 8 is a graph of hsa-miR-330-2-3p inhibiting the growth of Citrobacter;
FIG. 9 is a graph of growth of Citrobacter from hsa-miR-181-5 p;
FIG. 10 the effect of hsa-30a-5p, hsa-106a-5p, hsa-296-3p on bacterial growth;
FIG. 11 the effect of hsa-134-5p, hsa-4463, and hsa-145-5p on bacterial growth.
Detailed Description
The present invention will be further described with reference to the following examples.
Example 1 acquisition of aNK exosomes and structural features thereof
The NK system was expanded using transmembrane IL-21 trophoblasts using existing methods: PBMCs were isolated from peripheral venous blood from volunteers and feeder cells expressing transmembrane IL-21 and IL-2 were added after irradiation, during which time complete medium was added and cultured for 18 days.
Collecting aNK cell culture solution cultured for 18 days, and detecting the purity of aNK cells by a flow cytometer to reach more than 95%, wherein the culture solution is free from bacterial and mycoplasma pollution.
1.1aNK cell culture solution is centrifuged for 5min by a desk type low speed centrifuge at 400g to remove cell sediment, and the supernatant is collected and stored at 4 ℃ for later use.
1.2 purification of exosomes in culture broth using a hollow fiber tangential filtration System (Spectrum Laboratories KrosFlo Research II TFF System). First, cell debris was removed from the cell culture broth using a 0.45 μm mPES hollow fiber filtration column (P-S02-E45U-10-N); the filtrate is further concentrated by mPES hollow fiber filter column (S02-E300-05-N) with molecular weight cut-off of 300-kDa to obtain crude product of exosome; to further reduce the volume and remove residual media and salt ions, the crude exosome preparation was diluted with 3 volumes of PBS and concentrated using mPES hollow fiber filter column (D02-E300-05-N) with a molecular weight cut-off of 300-kDa, yielding very pure exosomes.
1.3 the obtained exosomes were diluted 100-fold with PBS, the particle size distribution of exosomes was detected using Zetasizer Nano ZSE system, and the detection results were analyzed with Dispersion Technology Software. As shown in FIG. 1, most of the aNK exosomes are distributed at 50-150nm, with peaks at 90 nm.
And 1.4, carrying out protein quantification on exosomes by using a BCA protein quantification kit, releasing proteins in the exosomes by using lysis solution, and detecting exosome Marker proteins CD63, ALIX and granzyme A, granzyme B and perforin which are unique to aNK exosomes by using a Werstern blot method. As shown in fig. 2, the aNK exosomes contained granzyme a, granzyme B and perforin specific to NK cells compared to the 293T exosomes.
1.5 resuspending the obtained exosomes with deionized water, placing a small amount of exosomes in a copper mesh with a carbon coating, removing redundant water, dyeing with 2% uranyl acetate, and observing the form and size of the exosomes by using a transmission electron microscope after natural drying. As shown in fig. 3, TEM results show that isolated aNK exosomes have a typical exosome structure, presenting a closed membrane structure with semi-transparent, elliptical interior, and varying sizes.
Example 2 sequencing of aNK exosomes miRNA
Sequencing of miRNA in aNK exosomes was entrusted to Nanjing and Gene biotechnology, Inc., according to aNK exosomes obtained in example 1. Library construction was performed using NEBNext Multiplex Small RNA Library Prep Set for Illumina (NEB, USA), and sequencing adapters were added to the samples to be sequenced. Samples were sequenced using the Illumina X-ten PE150 platform, with at least 300M reads per sample. In order to reduce false positives, independent sequences with a signal-to-noise ratio of greater than 100 were included in the calculation of miRDeep log-odds score and set the miRDeep log-odds score range from-10 to 10. in order to discover all new mirnas in the aNK exosomes, miRDeep score 0 was used as the threshold and all mirnas above the threshold were used as all new mirnas, as shown in fig. 4, 732 known mirnas were found in the sequencing (SEQ ID No. 1412-SEQ ID No. 2144). Besides, there are 1411 miRNAs (SEQ ID NO. 1-1411) with completely new sequences.
Example 3 antibacterial Properties of aNK exosomes and antibacterial Properties of aNK exosomes in combination with NK cells
In order to determine whether the exosome can inhibit the growth of bacteria, citrobacter (c.r.), escherichia coli, staphylococcus aureus, salmonella typhi (CT18), staphylococcus aureus (LAC), acinetobacter baumannii (XH386) were selected as test objects. The aNK exosomes obtained in example 1 were mixed with the bacteria in the above 6 in various ratios, and the number of bacteria was quantified by measuring Optical Density (OD). The results are shown in fig. 5, where the growth of e.coli, s.aureus, s.typhi (CT18) and s.aureus (LAC) showed a significant concentration-dependent inhibition with increasing exosome concentration compared to the negative control without exosomes. Meanwhile, the number of bacteria was quantified by detecting luciferase activity in citrobacter, and the intensity of bioluminescence decreased with the increase of the concentration of aNK exosomes, indicating that aNK exosomes can inhibit citrobacter in a concentration-dependent manner (fig. 6).
Further results showed that aNK exosomes were further enhanced in combination with NK cells' antibacterial effect relative to aNK cells (figure 7).
Example 4 antimicrobial Properties of miRNA of known sequence
The miRNA with known sequences obtained by screening in the example 2 are randomly divided into 8 groups, 30 samples are randomly selected from each group for antibacterial testing, and the results show that the miRNA all have antibacterial performance. Using hsa-miR-330-5p (SEQ ID NO.1571), hsa-miR-181a-2-3p (SEQ ID NO.1657), hsa-miR-30a-5p (SEQ ID NO.1503), hsa-miR-106a-5p (SEQ ID NO.1603), hsa-miR-296-3p (SEQ ID NO.1731), hsa-miR-134-5p (SEQ ID NO.1531), hsa-miR-4463(SEQ ID NO.2048) and hsa-miR-145-5p (SEQ ID NO.1586) in the 240 samples as an example, these miRNA analogs were artificially synthesized and subjected to the following antibacterial tests:
(1) hsa-miR-330-5p, hsa-miR-181-2-3p analogs were co-incubated at 1.25. mu.M, 2.5. mu.M, 5. mu.M and Citrobacter, and the number of bacteria was quantified by detecting OD 600. The test results are shown in fig. 8 and 9.
(2) hsa-miR-30a-5p, hsa-miR-106a-5p, hsa-miR-296-3p, hsa-miR-134-5p, hsa-miR-4463 and hsa-miR-145-5p analogs were incubated with Citrobacter at a concentration of 1.25. mu.M, and the number of bacteria was quantified by detecting OD 600. The test results are shown in FIGS. 10-11.
Compared with a negative control PBS group and an NC group, the hsa-miR-330-5p, hsa-miR-181-2-3p, hsa-miR-30a-5p, hsa-miR-106a-5p, hsa-miR-296-3p, hsa-miR-134-5p, hsa-miR-4463 and hsa-miR-145-5p which are randomly selected can obviously inhibit the growth of bacteria, and the effect of inhibiting the growth of the citrobacter by the hsa-miR-330-5p is most obvious.
Implementation 5 antimicrobial Properties of MiRNA of New sequence
The miRNA of the novel sequence obtained by screening in the example 2 is randomly divided into 10 groups, 30 samples are randomly selected from each group to carry out the anti-Citrobacter test, and the results show that the miRNA all have antibacterial performance. Hsa-miR-9502(chr7_17512, SEQ ID NO.878), hsa-miR-9543(chr1_354, SEQ ID NO.531), hsa-miR-9550(chr11_26139, SEQ ID NO.510), hsa-miR-9555(chr10_23533, SEQ ID NO.448), hsa-miR-9564(chrX _44483, SEQ ID NO.497), hsa-miR-9609(chr16_37097, SEQ ID NO.520), hsa-miR-9684(chr2_4515, SEQ ID NO.515), hsa-miR-9700(chr19_37125, SEQ ID NO.290), hsa-miR-9719(chr3_8592, SEQ ID NO.997), hsa-miR-978 _ 22492, SEQ ID NO. 2242, SEQ ID NO. 224978, SEQ ID NO. 2249847, SEQ ID NO. 9847, and SEQ ID NO. 6347 in the 300 samples, These miRNA analogs were artificially synthesized, for example, hsa-miR-9832(chr22_39917, SEQ ID NO.144) and hsa-miR-9857(chr8_19943, SEQ ID NO.1186), and subjected to the following antibacterial tests:
(1) hsa-miR-9502, hsa-miR-9543, hsa-miR-9550, hsa-miR-9555, hsa-miR-9564, hsa-miR-9609, hsa-miR-9684, hsa-miR-9700, hsa-miR-9719, hsa-miR-9773, hsa-miR-9825, hsa-miR-9832, hsa-miR-9857 analogue are incubated according to 1.25 mu M, 2.5 mu M, 5 mu M and Citrobacter, and the number of bacteria is quantified by detecting OD 600. The test results are shown in table 1.
(2) hsa-miR-9502, hsa-miR-9550, and hsa-miR-9609 analogs were incubated with Citrobacter at a concentration of 5. mu.M, and the number of bacteria was quantified by detecting OD 600.
Compared with a negative control PBS group and an NC group, the selected hsa-miR-9502, hsa-miR-9550 and hsa-miR-9609 can obviously inhibit the growth of bacteria, and the effect of inhibiting the growth of citrobacter by hsa-miR-9609 is most obvious.
TABLE 1
Implementation 5 anti-tumor Properties of miRNA with novel sequences
The miRNA of the whole new sequence obtained by screening in example 2 is randomly divided into 10 groups, 30 samples in each group are randomly selected for anti-tumor cell testing, and neuroblast CHLA-255 is used as a target cell. The results show that the compounds have the anti-tumor cell performance. In the 300 samples hsa-miR-9507(chr3_7489, SEQ ID NO.600), hsa-miR-9514(chr1_354, SEQ ID NO.531), hsa-miR-9758(chr1_131, SEQ ID NO.862), hsa-miR-9796(chr2_5702, SEQ ID NO.177), hsa-miR-10029(chr12_27203, SEQ ID NO.49), hsa-miR-10157(chr8_19314, SEQ ID NO.412), hsa-miR-10315(chr5_12999, SEQ ID NO.983), hsa-miR-10367(chr 5835025 _ 06, SEQ ID NO.660), hsa-miR-10434(chr7_19106, SEQ ID NO.769), and hsa-miR-17169 (chr 584 _ 17169, SEQ ID NO. 45) were used as anti-tumor synthetic experiments, and the anti-tumor analogs were synthesized as follows:
and (2) incubating hsa-miR-9507, hsa-miR-9514, hsa-miR-9758, hsa-miR-9796, hsa-miR-10029, hsa-miR-10157, hsa-miR-10229, hsa-miR-10315, hsa-miR-10367, hsa-miR-10434 and hsa-miR-10469 analogues according to 1.25 mu M, 2.5 mu M, 5 mu M and aNK exosomes for 12 hours, adding a miRNA and exosome mixture into the luciferase labelled neuroblastoma cells, and culturing for 48 hours. The survival rate of tumor cells is quantified by detecting changes in the level of fluorogenic substrate by the tumor cells. The test results are shown in Table 2, and it can be proved that the selected miRNAs such as hsa-miR-10029, hsa-miR-10367, hsa-miR-10434 and the like can remarkably inhibit the growth of tumor cells, and the growth inhibition effect of hsa-miR-10029 is most obvious.
TABLE 2
Sequence listing
<110> Zhejiang university
SHANGHAI BOKANG BIOTECHNOLOGY Co.,Ltd.
<120> application of NK cell exosome hsa-miR-9609 in antibiosis
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 20
<212> RNA
<213> Unknown (Unknown)
<400> 1
cggcggcucc agggaccugg 20
Claims (2)
1. An application of an exosome secreted by NK cells activated by transmembrane IL-21 in preparing an anti-citrobacter preparation, wherein miRNA of the exosome is hsa-miR-9609, and the sequence is cggcggcucc agggaccugg.
2. The use according to claim 1, characterized in that the exosomes are used for antibacterium alone or in combination with transmembrane IL-21 activated NK cells.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911001160.7A CN110613735B (en) | 2017-12-11 | 2017-12-11 | Application of NK cell exosome hsa-miR-9609 in antibiosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711309365.2A CN107998149B (en) | 2017-12-11 | 2017-12-11 | Application of NK cell exosome and related miRNA in antibiosis and antitumor |
CN201911001160.7A CN110613735B (en) | 2017-12-11 | 2017-12-11 | Application of NK cell exosome hsa-miR-9609 in antibiosis |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711309365.2A Division CN107998149B (en) | 2017-12-11 | 2017-12-11 | Application of NK cell exosome and related miRNA in antibiosis and antitumor |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110613735A CN110613735A (en) | 2019-12-27 |
CN110613735B true CN110613735B (en) | 2022-07-01 |
Family
ID=62058180
Family Applications (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911001208.4A Active CN110623981B (en) | 2017-12-11 | 2017-12-11 | Application of NK cell exosome hsa-miR-330-5p in antibiosis |
CN201911001139.7A Active CN110684770B (en) | 2017-12-11 | 2017-12-11 | Application of hsa-miR-10434 miRNA sequence in tumor resistance |
CN201911001156.0A Active CN110613728B (en) | 2017-12-11 | 2017-12-11 | Application of NK cell exosome hsa-miR-9773 in antibiosis |
CN201711309365.2A Active CN107998149B (en) | 2017-12-11 | 2017-12-11 | Application of NK cell exosome and related miRNA in antibiosis and antitumor |
CN201911001168.3A Active CN110664843B (en) | 2017-12-11 | 2017-12-11 | Application of NK cell exosome hsa-miR-9550 in antibiosis |
CN201911000477.9A Active CN110951729B (en) | 2017-12-11 | 2017-12-11 | Application of hsa-miR-10029 miRNA sequence in tumor resistance |
CN201911001160.7A Active CN110613735B (en) | 2017-12-11 | 2017-12-11 | Application of NK cell exosome hsa-miR-9609 in antibiosis |
CN201911001195.0A Active CN110613729B (en) | 2017-12-11 | 2017-12-11 | Application of NK cell exosome hsa-miR-181a-2-3p in antibiosis |
CN201911000506.1A Active CN110613727B (en) | 2017-12-11 | 2017-12-11 | Application of NK cell exosome hsa-miR-9502 in antibiosis |
CN201911000467.5A Active CN110669764B (en) | 2017-12-11 | 2017-12-11 | Application of hsa-miR-10367 miRNA sequence in tumor resistance |
Family Applications Before (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911001208.4A Active CN110623981B (en) | 2017-12-11 | 2017-12-11 | Application of NK cell exosome hsa-miR-330-5p in antibiosis |
CN201911001139.7A Active CN110684770B (en) | 2017-12-11 | 2017-12-11 | Application of hsa-miR-10434 miRNA sequence in tumor resistance |
CN201911001156.0A Active CN110613728B (en) | 2017-12-11 | 2017-12-11 | Application of NK cell exosome hsa-miR-9773 in antibiosis |
CN201711309365.2A Active CN107998149B (en) | 2017-12-11 | 2017-12-11 | Application of NK cell exosome and related miRNA in antibiosis and antitumor |
CN201911001168.3A Active CN110664843B (en) | 2017-12-11 | 2017-12-11 | Application of NK cell exosome hsa-miR-9550 in antibiosis |
CN201911000477.9A Active CN110951729B (en) | 2017-12-11 | 2017-12-11 | Application of hsa-miR-10029 miRNA sequence in tumor resistance |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911001195.0A Active CN110613729B (en) | 2017-12-11 | 2017-12-11 | Application of NK cell exosome hsa-miR-181a-2-3p in antibiosis |
CN201911000506.1A Active CN110613727B (en) | 2017-12-11 | 2017-12-11 | Application of NK cell exosome hsa-miR-9502 in antibiosis |
CN201911000467.5A Active CN110669764B (en) | 2017-12-11 | 2017-12-11 | Application of hsa-miR-10367 miRNA sequence in tumor resistance |
Country Status (1)
Country | Link |
---|---|
CN (10) | CN110623981B (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108424962B (en) * | 2018-05-25 | 2021-08-03 | 中国人民解放军陆军军医大学 | MiRNA detection marker for mesangial proliferative glomerulonephritis and diagnostic kit thereof |
CN109136224B (en) * | 2018-08-21 | 2022-03-18 | 上海交通大学医学院附属瑞金医院 | miR-221/222 and inhibitor thereof for preparing medicine for regulating liver fat deposition, liver fibrosis and hepatocellular carcinoma |
KR102089559B1 (en) * | 2018-08-31 | 2020-03-16 | 차의과학대학교 산학협력단 | Biomarker for diagnosing or predicting reactivity to FSH of ovary |
CN109295001A (en) * | 2018-11-14 | 2019-02-01 | 姜大奎 | A kind of compound excretion body of umbilical cord mesenchymal stem cells and preparation method thereof |
CN109369797B (en) * | 2018-12-06 | 2020-02-14 | 中南大学湘雅二医院 | Recombinant human IL-21 protein and preparation and application thereof |
CN109402269B (en) * | 2018-12-07 | 2022-04-01 | 湖北省农业科学院畜牧兽医研究所 | Application of reagent for detecting miRNA-217-5p in preparation of duck intestinal stress detection reagent |
CN109432050A (en) * | 2018-12-13 | 2019-03-08 | 王国胜 | A kind of composition of natural killer cells excretion body and macromolecular dendritic |
CN110283745B (en) * | 2019-06-27 | 2021-05-11 | 浙江工业大学 | Acinetobacter hospital FK2 and application thereof in degrading organic pollutants |
CN110643607B (en) * | 2019-10-28 | 2023-08-18 | 沈阳农业大学 | microRNA related to reproductive function of Liaoyu white cattle and obtaining method thereof |
CN111172112B (en) * | 2019-11-20 | 2021-05-25 | 广东医科大学附属医院 | Full transcriptome expression profile of exosome and construction method and application thereof |
CN110721196B (en) * | 2019-11-27 | 2021-07-06 | 沣潮医药科技(上海)有限公司 | Application of decidua NK cells and cell subset source exosomes thereof in preparation of medicines and adjuvant treatment agents for infertility related diseases |
CN110951694B (en) * | 2019-12-30 | 2021-07-06 | 北京鼎成肽源生物技术有限公司 | Preparation method of autologous trophoblast and culture method of SNK cells |
US20210277358A1 (en) * | 2020-03-05 | 2021-09-09 | Korea Research Institute Of Bioscience | METHOD FOR PRODUCING MEMORY-LIKE NK CELLS WITH ABILITY TO EXPRESS HIGHER LEVELS OF NCRS, CYTOTOXICITY, AND IFN-y THAN NK CELLS IN HUMAN PERIPHERAL BLOOD |
CN111440800B (en) * | 2020-04-20 | 2023-04-28 | 南通大学附属医院 | miRNA-128-3p of targeted Galectin-3 gene and application of miRNA-128-3p in pancreatic cancer resistance |
CN111733157B (en) * | 2020-07-01 | 2023-12-19 | 上海嘉慷生物工程有限公司 | Method for obtaining specific miRNA of targeted virus |
CN111494416B (en) * | 2020-07-01 | 2020-09-15 | 上海嘉慷生物工程有限公司 | Application of NK cell exosome and related miRNA in preparation of COVID-19 virus inhibitor |
WO2022000374A1 (en) * | 2020-07-01 | 2022-01-06 | 上海嘉慷生物工程有限公司 | Covid-19 virus inhibitor |
CN112626209A (en) * | 2020-12-22 | 2021-04-09 | 绵竹市人民医院 | miRNA marker for ovarian cancer diagnosis, application thereof and diagnosis kit |
CN112626017B (en) * | 2021-01-08 | 2023-04-07 | 深圳市汉科生命工程有限公司 | Preparation method and application of NK cell exosome |
CN112980788B (en) * | 2021-03-08 | 2021-11-05 | 河北森朗生物科技有限公司 | Preparation method of NK (natural killer) cells with low expression of CD7 |
CN114836379B (en) * | 2021-12-09 | 2023-05-12 | 浙江大学 | Method for obtaining active component of anti-tumor blood medicine and application thereof |
CN114053336B (en) * | 2022-01-10 | 2022-04-08 | 北京荟科柘生物科技有限公司 | Preparation method and application of NK cell freeze-dried powder |
CN114908036A (en) * | 2022-05-07 | 2022-08-16 | 河北医科大学 | Application of integrin alpha 5 beta 1 receptor in preparation of antibacterial exosomes |
CN114807139B (en) * | 2022-05-11 | 2023-11-24 | 上海海洋大学 | Regenerated small molecule miRNA-XU2 and application thereof |
WO2024000092A1 (en) * | 2022-06-27 | 2024-01-04 | 浙江大学 | Active component of anti-oral cancer drug and use thereof |
CN115521914B (en) * | 2022-10-12 | 2024-04-19 | 西北工业大学 | In-vitro amplification system and method for human primary natural killer cells |
CN116218773B (en) * | 2023-02-28 | 2024-01-23 | 广州蒽恺赛生物科技有限公司 | NK cell exosome of specific targeting bacteria and application thereof |
CN117815257A (en) * | 2024-01-08 | 2024-04-05 | 南方医科大学深圳医院 | Application of miR-760-3p in preparation of medicine for preventing and treating type 2 diabetes |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2931485A1 (en) * | 2008-05-23 | 2009-11-27 | Centre Nat Rech Scient | ANTITUMOR VACCINE COMPRISING MODIFIED TUMOR CELLS |
CN103703142A (en) * | 2011-01-26 | 2014-04-02 | 西菲伊德公司 | Methods of detecting lung cancer |
WO2014089029A1 (en) * | 2012-12-03 | 2014-06-12 | Ohio State Innovation Foundation | Activation of innate immunity by mirna for cancer and infection treatment |
CN105708861A (en) * | 2016-03-16 | 2016-06-29 | 沈慧勇 | Novel application of exosome of mesenchymal stem cell source |
CN106716132A (en) * | 2014-08-13 | 2017-05-24 | 新加坡科技研究局 | Diagnosis of cancer |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016535009A (en) * | 2013-10-17 | 2016-11-10 | チルドレンズ ホスピタル ロサンゼルス | Methods of antibody-dependent exosome therapy |
CN107119015B (en) * | 2017-04-27 | 2020-08-11 | 贺飞 | Exosome, preparation method thereof and application thereof in preparation of medicine for treating lung cancer |
-
2017
- 2017-12-11 CN CN201911001208.4A patent/CN110623981B/en active Active
- 2017-12-11 CN CN201911001139.7A patent/CN110684770B/en active Active
- 2017-12-11 CN CN201911001156.0A patent/CN110613728B/en active Active
- 2017-12-11 CN CN201711309365.2A patent/CN107998149B/en active Active
- 2017-12-11 CN CN201911001168.3A patent/CN110664843B/en active Active
- 2017-12-11 CN CN201911000477.9A patent/CN110951729B/en active Active
- 2017-12-11 CN CN201911001160.7A patent/CN110613735B/en active Active
- 2017-12-11 CN CN201911001195.0A patent/CN110613729B/en active Active
- 2017-12-11 CN CN201911000506.1A patent/CN110613727B/en active Active
- 2017-12-11 CN CN201911000467.5A patent/CN110669764B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2931485A1 (en) * | 2008-05-23 | 2009-11-27 | Centre Nat Rech Scient | ANTITUMOR VACCINE COMPRISING MODIFIED TUMOR CELLS |
CN103703142A (en) * | 2011-01-26 | 2014-04-02 | 西菲伊德公司 | Methods of detecting lung cancer |
WO2014089029A1 (en) * | 2012-12-03 | 2014-06-12 | Ohio State Innovation Foundation | Activation of innate immunity by mirna for cancer and infection treatment |
CN106716132A (en) * | 2014-08-13 | 2017-05-24 | 新加坡科技研究局 | Diagnosis of cancer |
CN105708861A (en) * | 2016-03-16 | 2016-06-29 | 沈慧勇 | Novel application of exosome of mesenchymal stem cell source |
Non-Patent Citations (4)
Title |
---|
MicroRNA regulation of natural killer cells;RyanP.Sullivan等;《Fronters in Immunology》;20130228;第4卷;第1-12页 * |
MicroRNA transcriptomes of distinct human NK cell populations identify miR-362-5p as an essential regulator of NK cell function;Fang Ni等;《Scientific Reports》;20150325;第5卷;第1-11页 * |
microRNA在免疫细胞中作用的研究进展;张学勇等;《细胞与分子免疫学杂志》;20151231;第31卷(第5期);第704-708页 * |
Molecular mechanisms of natural killer cell activation in response to cellular stress;CJ Chan等;《Cell Death and Differentiation》;20130412;第21卷;第5-14页 * |
Also Published As
Publication number | Publication date |
---|---|
CN110664843A (en) | 2020-01-10 |
CN110613727A (en) | 2019-12-27 |
CN110613729A (en) | 2019-12-27 |
CN110613727B (en) | 2022-06-21 |
CN110623981A (en) | 2019-12-31 |
CN110664843B (en) | 2022-07-01 |
CN110684770B (en) | 2021-01-12 |
CN110669764B (en) | 2020-12-11 |
CN110951729A (en) | 2020-04-03 |
CN110613728A (en) | 2019-12-27 |
CN110623981B (en) | 2022-07-01 |
CN110613728B (en) | 2022-06-21 |
CN107998149B (en) | 2020-05-19 |
CN110613729B (en) | 2022-06-21 |
CN107998149A (en) | 2018-05-08 |
CN110951729B (en) | 2021-01-12 |
CN110613735A (en) | 2019-12-27 |
CN110669764A (en) | 2020-01-10 |
CN110684770A (en) | 2020-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110613735B (en) | Application of NK cell exosome hsa-miR-9609 in antibiosis | |
TWI778025B (en) | Antibiotic testing and screening system | |
US11458177B2 (en) | Enterococcus faecium bacteriophage Ent-FAP-4 and use for inhibiting Enterococcus faecium proliferation of same | |
JP2011510646A (en) | Non-pathogenic and / or attenuated bacteria capable of inducing apoptosis in macrophages, methods for their production and use | |
Zou et al. | Frequency of antimicrobial resistance and integron gene cassettes in Escherichia coli isolated from giant pandas (Ailuropoda melanoleuca) in China | |
CN112940982A (en) | Snakehead source Bacillus belezii and application thereof | |
Shehabi et al. | Characterization of antimicrobial resistance and class 1 integrons found in Escherichia coli isolates from human stools and drinking water sources in Jordan | |
JPWO2011058923A1 (en) | Antibacterial agent for quinolone-resistant bacteria and its use | |
KR100817548B1 (en) | Marine microorganism, pseudomonas sp. uj-6, producing antibiotics against methicillin resistance staphylococcus aureus | |
Raymant et al. | Macrophage-fibroblast JAK/STAT dependent crosstalk promotes liver metastatic outgrowth in pancreatic cancer | |
CN112646785B (en) | High-temperature-resistant virulent proteobacterium bacteriophage RDP-SA-20018 and application thereof | |
CN111925959B (en) | Multi-drug-resistant staphylococcus dolphin and application thereof | |
US20240050499A1 (en) | Compositions and methods for inhibiting the proliferation of enterotoxigenic bacteroides fragilis | |
Gao et al. | Single‐cell transcriptomic sequencing identifies subcutaneous patient‐derived xenograft recapitulated medulloblastoma | |
US20240041958A1 (en) | Compositions and methods for inhibiting the proliferation of enterotoxigenic bacteroides fragilis | |
KR20230010741A (en) | Compositions and methods for inhibiting the growth of pathogenic E. coli | |
González | “In vivtro”-a 3D cell culture system to analyze the impact of probiotic E. coli Nissle 1917 on epithelial cells | |
EP4319781A1 (en) | Compositions and methods for inhibiting the proliferation of enterotoxigenic bacteroides fragilis | |
Asmaa | Isolation and Identification of Hyaluronidase Producing Staphylococcus aureus | |
Bavananthasivam | Inhibition of the Growth of Mannheimia Haemolytica by Other Gram Negative Bacteria | |
Sharaf et al. | Comparison between ica operon expression and biofilm formation in methicillin-resistant staphylococcus aureus isolated from central venous catheters under different environmental conditions | |
M Faisal | Detection of Sex Pheromone Production in Isolates of Enterococcus faecalis that Increases Conjugation Frequency |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |